Skip Navigation

Melatonin Is Neuroprotective in Experimental Streptococcus pneumoniae Meningitis

  1. Joachim Gerber1,
  2. Miriam Lotz1,
  3. Sandra Ebert1,
  4. Susanne Kiel1,
  5. Gerald Huether2,
  6. Ulrich Kuhnt3 and
  7. Roland Nau1
  1. Departments of
  2. 1Neurology and
  3. 2Psychiatry, Georg-August-University, and
  4. 3Department of Neurobiology, Max-Planck-Institute for Biophysical Chemistry, Göttingen, Germany
  1. Reprints or correspondence: Dr. Roland Nau, Dept. of Neurology, Georg-August-University, Robert-Koch-Str. 40, D-37075 Göttingen, Germany (rnau{at}gwdg.de)
 
Next Section

Abstract

Neuronal injury in bacterial meningitis is a consequence of the direct toxicity of bacterial components and inflammatory and oxidative mechanisms. Adjunctive therapy with melatonin was investigated in vitro and in experimental meningitis. Cellular damage was reduced by treatment with melatonin in organotypic hippocampal cultures (P<.001) and in human SH-SY5Y cells (P<.01). Rabbits were infected intracisternally with Streptococcus pneumoniae and received either melatonin (20 mg/kg body weight/24 h; n=12) or saline (n = 11) intravenously. Twelve hours later, all rabbits received ceftriaxone (10 mg/kg body weight/h). The density of apoptotic dentate granule cells was lower in melatonin-treated rabbits (81.8±52.9 vs. 227.5±127.9 cells/mm2; P=.002). The activity of superoxide dismutase in the hippocampal formation was higher (P=.04), and nitrite concentrations in cerebrospinal fluid were lower, after treatment with melatonin (P=.003). Melatonin reduced neuronal injury in vitro and in experimental meningitis, and it may be suitable as adjunctive therapy in human meningitis

Neuronal injury in bacterial meningitis is a consequence of leukocyte invasion into the central nervous system (CNS), stimulation of microglia and resident macrophages, and direct toxicity of bacterial components on cerebral endothelium and neuronal cells [1]. The formation and release of free radicals is a key event in the cascade that eventually leads to neuronal injury. Pneumococcal cell-wall components attract leukocytes into the CNS that release reactive oxidants and proteolytic enzymes [2, 3]. Bacterial cell walls of Streptococcus pneumoniae and group B streptococci induce nitric oxide (NO) production in glial cells and induce neurotoxicity [4]. Moreover, the bacterium S. pneumoniae itself is able to release hydrogen peroxide [5, 6]. Treatment with the nonbacteriolytic antibiotic rifampin reduces the production of reactive oxygen species of cerebrospinal fluid (CSF) phagocytes and hippocampal injury in experimental S. pneumoniae meningitis [7]. Antiinflammatory and antioxidative treatment strategies are therefore promising with respect to minimizing cerebral complications in bacterial meningitis

The antioxidant N-acetyl-5-methoxytryptamine (melatonin) is a derivate of the amino acid tryptophan. Physiologically, melatonin is the major secretory product of the pineal gland. It is also synthesized in extrapineal tissues, such as the retina and enterochromaffin cells of the gastrointestinal tract [8, 9]. Melatonin is released by the pineal gland in a diurnal rhythm and is involved in the regulation of the circadian rhythm, sleep, and reproduction [10]. So far, 2 classes of membrane-bound melatonin receptors, the G-protein coupled receptor family MT1 and MT2 and the quinone reductase enzyme family MT3, have been identified [11 –14]. Moreover, melatonin may act by stimulating nuclear receptors [15, 16]. Both receptor-mediated and non–receptor-mediated effects have been proposed for melatonin. Melatonin is a potent broad-spectrum antioxidant. It scavenges a variety of oxygen and nitrogen species, including the hydroxyl radical, hydrogen peroxide, singlet oxygen, NO, and peroxynitrite, and it is irreversibly oxidized to 5-methoxy-N-acetyl-N-formyl-kynuramine [17]. Moreover, melatonin stimulates the expression of several antioxidative enzymes, such as superoxide dismutase (SOD) and glutathione peroxidase [18 –21]

High-dose administration of melatonin inhibits neuronal and glial injury in various models of disease, including cerebral artery occlusion and epileptic seizures [22 –26]. Surgical removal of the pineal gland exaggerates cellular damage caused by free radicals during oxidative challenge [27, 28], which indicates that endogenous melatonin concentrations already possess antioxidative properties. Because oxidative mechanisms play a central role in the pathophysiology of bacterial meningitis and contribute to neuronal injury and brain damage [1 –3], we studied the efficacy of melatonin in cell cultures exposed to S. pneumoniae and oxidative stress and in a rabbit model of pneumococcal meningitis

Previous SectionNext Section

Materials and Methods

Organotypic hippocampal cultures Six- to 8-day-old NMRI mice bred at the animal care facility of the Max-Planck-Institute for Biophysical Chemistry (Göttingen, Germany) were decapitated. The hippocampal formation was prepared and cut transversally with a McIlwain tissue chopper into 400-μm-thick slices under sterile conditions. Slices were kept in Grey’s balanced salt solution supplemented with 36 mmol/L d-glucose for 30 min at 4°C. Thereafter, slices were embedded in plasma clots on glass coverslips, which were then coagulated by the addition of thrombin. Coverslips were transferred to plastic culture tubes that contained culture medium composed of 50% Hanks’ basal medium, 25% Hanks’ balanced salt solution, 25% heat-inactivated horse serum supplemented with glutamine (1 mmol/L), and d-glucose (36 mmol/L). Culture tubes were placed in a roller device rotating at 10 revolutions/h in an air-ventilated incubator at 36°C. After 12 days, cultures were challenged with 107 cfu/mL of a living unencapsulated S. pneumoniae R6 strain for 48 h. The unencapsulated strain was chosen because the capsule masks the cell-wall epitopes that stimulate the innate immune system. Ceftriaxone (1 μg/mL) was administered at the same time, to prevent bacterial growth. Melatonin (Sigma-Aldrich) was dissolved in medium at a concentration of 0.1 μg/mL. Organotypic hippocampal cultures (n=17 each group) were treated with S. pneumoniae R6 and ceftriaxone or with S. pneumoniae R6, ceftriaxone, and melatonin. Negative control cultures were not exposed to S. pneumoniae R6 and received only melatonin and ceftriaxone

Propidium iodide (PI) staining of organotypic hippocampal cultures The vital dye PI (Sigma-Aldrich) was used to determine cell-membrane damage in organotypic hippocampal cultures. With the loss of cell membrane integrity, PI enters the cell and binds to DNA. PI fluorescence is therefore related to necrotic or late apoptotic cell death. After treatment with S. pneumoniae and melatonin for 48 h, medium was replaced by PI (25 μg/mL dissolved in medium), followed by incubation for 1 h at 36°C. Thereafter, organotypic hippocampal cultures were examined by dark-field fluorescence microscopy (Zeiss; Axiophot). Fluorescence intensity was recorded by a CCD camera (Zeiss Axiocam). Subsequently, cultures were fixed with 4% buffered formaldehyde, to induce maximum membrane damage; washed briefly in 0.1 mol phosphate buffer; restained with medium that contained PI; and again examined by dark-field fluorescence microscopy. Light intensity was quantified offline with the image analysis software Sigma Scan Pro (version 5.0; Jandel Scientific Software). Cell damage induced in the dentate gyrus was calculated as the ratio of light intensity before fixation divided by the light intensity after fixation ×100 (percentage of PI uptake)

SH-SY5Y neuroblastoma cell cultures To examine the effects of melatonin on cell viability under conditions of oxidative stress, SH-SY5Y human neuroblastoma cells were exposed to 3-morpholinosydnonimine (SIN-1; Calbiochem). At physiological pH, SIN-1 spontaneously decays to NO and superoxide anion radicals. SH-SY5Y human neuroblastoma cells were maintained in RPMI 1640 medium (Biochrom) at 37°C with 5% CO2. SH-SY5Y cells were seeded into 96-well plates at a density of 105 cells/cm2, and cultures were treated with medium that contained SIN-1 (500 μmol/L) or SIN-1 plus melatonin at concentrations of 0.1, 1, 10, 100, and 1000 μg/mL (n=6 for each group). Four hours later, cell viability was determined

Primary mouse microglial cell culture Primary cultures of microglial cells were established from brains of newborn C57/Bl6 mice (1–3 days old). After removal of the meninges, cells were mechanically dissociated and suspended in Dulbecco’s modified Eagle medium with Glutamax I (Gibco) supplemented with 10% fetal calf serum (FCS), 100 U/mL penicillin, and 100 μg/mL streptomycin. Cells were plated at a density of 2 brains/T75 culture flask (Corning Costar) and incubated at 37°C with 5% CO2. After 10–14 days, the confluent mixed glial cultures were shaken 200 times/min for 30 min. Microglial cells in the supernatants were replated in 96-well cell-culture plates at a density of 75,000 cells/well. Stimulation of microglial cells was performed with the Toll-like receptor (TLR)–2 agonist tripalmitoyl-S-glyceryl-cysteine (Pam3Cys-OH; EMC-Microcollections) for 24 h in the presence of interferon (IFN)–γ (100 U/mL). Cultures were treated with Pam3Cys (0.1 μg/mL) or Pam3Cys plus melatonin at concentrations of 10, 100, 300, and 1000 μg/mL (n=8 for each group). Negative control cultures received IFN-γ only. The release of NO into the supernatant was quantified by measurement of the stable reaction product nitrite, by use of the Griess reagent. Microglial cells were assayed for cell viability

Measurement of cell viability The cell viability of SH-SY5Y and microglial cells was determined by use of the WST-1 cell proliferation reagent (Roche Applied Science). The assay is based on the cleavage of the tetrazolium salt WST-1 by active mitochondria, which produces a soluble formazan. Cells were incubated with WST-1 for 2 h. Then, the formazan dye formed was quantified by measuring the optical density at 490 nm by use of a Genios multiplate reader (Tecan). The absorbance directly correlates with the number of metabolically active cells

Rabbit model of experimental meningitis A penicillin-sensitive S. pneumoniae type 3 strain originally isolated from an adult patient with meningitis (MIC, 0.03 μg/mL; minimal bactericidal concentration, 0.06 μg/mL) was used (gift from M. G. Täuber, University of Bern, Switzerland). After the intramuscular administration of anesthesia with ketamine (25 mg/kg body weight) and xylazine (5 mg/kg body weight), New Zealand White rabbits were inoculated intracisternally by suboccipital puncture with 1×106 cfu of S. pneumoniae. Thereafter, rabbits received, intravenously, either 20 mg/kg body weight melatonin (Sigma-Aldrich) dissolved in 50 mL of saline (n=12) or an equal amount of saline (n=11), by a continuous infusion, for 24 h. Anesthesia was maintained by the intravenous administration of urethane for the entire duration of the experiment (24 h). Ceftriaxone (Rocephin; Hoffmann-LaRoche) was administered intravenously for 12–24 h after infection (loading dose, 20 mg/kg body weight; maintenance dose, 10 mg/kg body weight/h). Blood and CSF were drawn at 12, 14, 17, 20, and 24 h after infection. Pneumococcal CSF titers were determined by plating 10 μL of undiluted CSF and serial 10-fold dilutions of CSF on blood agar plates. White blood cells (WBCs) were counted in a Fuchs-Rosenthal hemocytometer. Protein content and lactate concentrations in CSF were measured by colorimetric assays (BCA Protein test; Pierce, and Lactate PAP test; Greiner Biochemica)

At 24 h after infection, rabbits were killed by an intracardial injection of 3 mL of 7.45% potassium chloride, and brains were removed. The hippocampal formation of the right hemisphere was immediately frozen at −80° C. The left hemisphere was fixed in 4% formaline for immunohistochemical analysis

In situ tailing (IST) Deparaffinized and hydrated 1-μm-thick sections were treated with 50 μg/mL proteinase K (Sigma) for 15 min at 37°C in a reaction mixture that contained 10 μL of 5× tailing buffer, 1 μL of digoxigenin DNA labeling mix, 2 μL of cobalt chloride, 12.5 U of terminal transferase, and the amount of distilled water necessary to give a volume of 50 μL. After washing, the sections were incubated with 10% FCS for 15 min at room temperature and then washed again. A solution of alkaline phosphatase–labeled anti–digoxigenin antibody in 10% FCS (1:250) was placed on the sections for 60 min at 37°C. The color reaction (black) was developed with 4-nitroblue-tetrazolium (NBT)–chloride/5-bromine-4-chloride-3-indolyl-phosphate. The sections were counterstained with nuclear fast red–aluminum hydroxide (reagents from Roche)

Quantification of apoptotic neurons A blinded observer (J.G.) used an imaging system (BX51; Olympus, and software AnalySIS version 3.2; Soft Imaging System) to count dentate granule cells labeled by the IST reaction and to measure the area of the granular cell layer of the dentate gyrus. Adjacent sections stained by hematoxylin-eosin showed morphological features of apoptosis in the same neurons. The density of apoptotic neurons was expressed as the number of marked cells per square millimeter of the granular cell layer

Determination of SOD activity The tissue of the hippocampal formation was homogenized in PBS, and cells were lysed by ultrasound and a cell lysis solution (SOD kit; R&D Systems). The concentration of hippocampal tissue in this solution was 100 mg/mL. Tissue homogenates were centrifuged at 14,000 g and 100 μL of the supernatants (equivalent to 10 mg of hippocampal tissue) was used for measurements. In the assay, the conversion of xanthine to uric acid and hydrogen peroxide by a xanthine oxidase generates superoxide ions, which convert NBT to NBT-diformazan. The activity of SOD reduces the concentration of superoxide ions and, thereby, of NBT-diformazan, which is detectable by light absorption at 560 nm

Nitrite assay The release of NO into the supernatant of microglial cell cultures and into the CSF of rabbits 24 h after infection was quantified by the measurement of nitrite, by use of Griess reagent; 100 μL of the samples was mixed with 100 μL of Griess reagent (equal volumes of 1% sulfonilamide in 30% acetate and 0.1% N-[1-naphthyl]ethylenediamine in 60% acetate) in a 96-well plate. After 10 min, the optical density at 570 nm was measured with a Genios multiplate reader (Tecan). Concentrations were calculated by comparison of absorptions with a standard curve

RIA for the quantification of melatonin Melatonin concentrations in serum and CSF were measured by RIA that used a specific antibody (G/S 704-6483; Guildhay Antisera). The detection limit of the assay (at which 5% of the ligand is displaced) was 1 pg/300 μL. Intra- and interassay variation were 6% and 12%, respectively. The results obtained with the RIA technique were validated by high-performance liquid chromatography measurements with electrochemical detection [29, 30]

Statistics Data were expressed as means ± SDs. Groups from in vitro experiments were compared by the 2-tailed parametric 1-way analysis of variance, and P values were adjusted for repeated testing by use of Bonferroni’s multiple comparison test. Data from animal experiments were compared by unpaired t test. Bacterial titers in CSF were used for log-linear regression analysis. P<.05 was considered to be statistically significant

Previous SectionNext Section

Results

Protection by melatonin against cellular damage in S. pneumoniae –treated organotypic hippocampal cultures and in SIN-1–treated human SH-SY5Y cells In organotypic hippocampal cultures exposed to a pneumococcal R6 strain, cellular damage in the dentate gyrus, as indicated by PI fluorescence, was lower after treatment with melatonin at a concentration of 0.1 μg/mL (P<.001). Negative control cultures without exposure to S. pneumoniae showed either very low or no fluorescence (figure 1)

Figure 1
View larger version:
Figure 1

Cellular damage in the dentate gyrus of organotypic hippocampal cultures quantified as uptake of propidium iodide 48 h after challenge with 107 cfu/mL of a pneumococcal R6 strain. Cultures were treated with Streptococcus pneumoniae and ceftriaxone (SP) or with S. pneumoniae ceftriaxone, and melatonin (melatonin). Control cultures were not exposed to S. pneumoniae (medium) (mean ± SD; ***P<.001, melatonin and medium vs. SP)

In SH-SY5Y cells, melatonin was capable of reducing oxidative cell damage caused by treatment with SIN-1 (P<.01). The concentrations required for neuroprotection, however, were higher than those that were effective in organotypic hippocampal cultures. The observed effect was dose dependent: melatonin at a concentration of 1 μg/mL substantially reduced cellular damage. Protection was maximal at 10 μg/mL. Higher concentrations of melatonin did not increase the protective effect. Neuroprotection was abolished at a concentration of 1 mg/mL (figure 2A )

Figure 2
View larger version:
Figure 2

A Cell viability in human SH-SY5Y cells 4 h after challenge with SIN-1 (500 μmol/L) and SIN-1 together with melatonin at several concentrations (mean ± SD; **P<.01 and *P<.05, SIN-1 plus melatonin vs. SIN-1). B Concentration of nitrite in the supernatant of microglial cell cultures after stimulation with tripalmitoyl-S-glyceryl-cysteine (P3C) and P3C together with melatonin (mean ± SD; ***P<.001 and **P<.01, P3C plus melatonin vs. P3C). Co, control group (medium and interferon-γ only

Lower nitrite concentrations in microglial cell cultures treated with melatonin Nitrite concentrations in supernatants of microglial cell cultures after stimulation with the TLR2 agonist Pam3Cys were reduced by treatment with melatonin (P<.001). This effect was dose dependent, reaching a maximum at a concentration of 1 mg/mL (figure 2B ). The decrease in nitrite concentrations in supernatants was not caused by toxic effects of melatonin: cell viability, as determined by the WST-1 cell proliferation reagent, showed no significant differences between melatonin-treated and control cultures (data not shown)

CSF parameters and concentrations of melatonin in experimental pneumococcal meningitis Bacterial titers (mean ± SD) in CSF determined 12 h after inoculation were 6.3±0.4 log cfu/mL in melatonin-treated rabbits and 6.5±0.9 log cfu/mL in control rabbits (P=.5). The bactericidal rate was −0.63 ± 0.14 Δlog cfu/mL/h in rabbits that received adjunctive melatonin therapy and -0.63±0.08 Δlog cfu/mL/h in control rabbits treated with ceftriaxone alone (P=.95). CSF lactate levels, protein concentrations, and WBC counts increased during the course of the experiment in both groups, and no significant differences between melatonin-treated and control rabbits were noted (table 1). Twenty-four hours after infection, the CSF concentration of nitrite, a stable reaction product of the reactive oxygen species NO, was lower in rabbits treated with melatonin and ceftriaxone, compared with rabbits treated with ceftriaxone alone (1.66±0.15 vs. 2.41±0.76 μmol/L; P = .003)

Melatonin readily entered the CSF. Levels in CSF 24 h after the start of treatment were ∼20% of the corresponding serum concentrations. In melatonin-treated rabbits, CSF concentrations increased from 0.03±0.02 ng/mL before treatment to 124±86.1 ng/mL 24 h later (table 1)

Marked decrease of neuronal cell death in experimental pneumococcal meningitis after treatment with melatonin  The frequency of apoptotic neurons in the dentate gyrus of the hippocampal formation was lower after treatment with melatonin and ceftriaxone than after treatment with ceftriaxone alone (81.8±52.9 vs. 227.2±127.9 cells/mm2; P=.002) (figures 3A and 4)

Figure 3
View larger version:
Figure 3

Density of apoptotic neurons in the dentate gyrus of the hippocampal formation (A) and activity of superoxide dismutase (U/10 mg tissue) in the hippocampal formation (B) 24 h after infection in rabbits treated with ceftriaxone and melatonin (melatonin) or ceftriaxone alone (control) (mean ± SD; **P=.002 and *P=.04, melatonin vs. control)

Figure 4
View larger version:
Figure 4

Apoptotic neurons (in situ tailing) in the dentate gyrus of the hippocampal formation 24 h after induction of bacterial meningitis in rabbits representative for treatment with ceftriaxone (A) or ceftriaxone and melatonin (B). Apoptosis was identified by morphology and DNA fragmentation, as described in Materials and Methods. Scale bar, 50 μm

Increased activity of SOD in melatonin-treated rabbits In brain homogenates of the hippocampal formation, the activity of SOD was higher in rabbits treated with melatonin than in control rabbits. SOD concentrations were 6.29±2.24 U/10 mg of hippocampal tissue after treatment with melatonin and 4.29 ± 1.65 U/10 mg in control rabbits that received only ceftriaxone (P=.04) (figure 3B )

Previous SectionNext Section

Discussion

The formation of reactive oxygen species and the failure of endogenous antioxidant mechanisms has been considered to be important for cellular damage in aging and in a variety of neurodegenerative diseases [31 –34]. Similarly, oxidative mechanisms contribute to acute brain damage, such as cerebral ischemia [34]. The excessive formation of reactive oxygen and nitrogen species has also been considered to be a key event in the pathophysiology of bacterial meningitis. Hydroxyl radicals and other compounds mediate cell death by membrane peroxidation, breakdown of the protein structure, and DNA damage. Finally, intracellular calcium increase, energy depletion, and caspase activation are the effectors of cell death in meningitis [1, 3]. Several antioxidant treatment strategies have been tested so far in bacterial meningitis. The radical scavenger α-phenyl-tert-butyl nitrone (PBN) prevented hippocampal and neocortical injury in an infant rat model of group B streptococcal meningitis [2]. The antioxidants N-acetylcysteine, deferoxamine, and trylizad-mesylate reduced cortical injury, but not hippocampal cell death, in S. pneumoniae meningitis [35]. Conversely, hippocampal damage and learning deficits were more pronounced after treatment with PBN in the same model [36]. Whether neuroprotection or detrimental side effects prevail depends not only on the animal model and the causative organism used but also on the toxic side effects of the antioxidant drug [36, 37]

The antioxidant melatonin is tolerated in large doses by humans and animals without producing severe adverse effects. In rats, melatonin administered at concentrations of 200 mg/kg body weight/day had no maternal toxicity and no detrimental effects on prenatal survival, fetal body weight, or the incidence of fetal malformations [38]. Melatonin is a compound that is endogenously produced at concentrations that are effective to protect against the oxidative stress that accompanies aging or neurodegenerative disorders [28, 32]. In acute cerebral diseases, however, adjunctive treatment with melatonin maximizes antioxidative effects. This strategy has been investigated in various experimental models of CNS injury but not yet in bacterial meningitis. In models of head trauma and cerebral ischemia, treatment with melatonin reduced the volume of contusion or cerebral infarction [25, 26, 39, 40]

In various models of bacterial meningitis and in human autopsy cases, neuronal injury has been frequently shown to occur in the hippocampal formation, and the apoptosis of dentate granule cells is a common feature [36, 41 –43]. In the present study, organotypic hippocampal cultures exposed to S. pneumoniae were used as a model of brain-tissue damage in bacterial meningitis. Both apoptotic and necrotic cell death has been observed in this model [44]. Melatonin was capable of reducing cellular damage in the dentate gyrus, as indicated by PI fluorescence. Similarly, in human SH-SY5Y cells treated with SIN-1 to induce oxidative stress, melatonin alleviated cellular damage. In the rabbit model of ceftriaxone-treated pneumococcal meningitis, neuronal damage in the hippocampal formation was significantly reduced by melatonin administered continuously during the experimental period

The nitrite concentration both in the supernatant of Pam3Cys-stimulated microglial cells and in the CSF of infected rabbits was reduced by melatonin. The effective melatonin concentrations, however, were higher in cultures of single cell types than in organotypic hippocampal cultures and in vivo. Melatonin has been shown to increase mRNA expression and the activity of glutathione peroxidase and SOD [18, 19]. In accordance with these findings, the activity of SOD was increased in the hippocampal formation of melatonin-treated rabbits in the present study. The neuroprotective effects of melatonin in complex systems are probably mediated not only by direct scavenging of free radicals but also by the stimulation of SOD and, possibly, other antioxidant enzymes

Immunmodulatory effects of melatonin have been postulated [45]. Results of studies, however, concerning melatonin as a regulator of the immune system have been inconsistent. Cytokine production in lipopolysaccharide-stimulated macrophage and microglial cell lines was not altered by melatonin, which suggests that melatonin is not a prominent modulator of macrophage and microglia function [46]. Consistent with this notion, melatonin did not influence parameters of inflammation within the subarachnoid space (CSF lactate levels, protein concentrations, and number of leukocytes) in the present study

Melatonin also influences the expression of neurotrophic factors, which may promote cell survival: in rat glioma cells and in dopaminergic striatal neurons, melatonin induced an enhanced mRNA expression of glial cell line–derived neurotrophic factor [47, 48]. In contrast to other antioxidants—such as N-acetylcysteine or deferoxamine, which, in experimental meningitis, relieved only neocortical neuronal injury and not hippocampal damage [35]—melatonin was effective in reducing neuronal apoptosis in dentate granule cells, the most frequent site of neuronal injury in bacterial meningitis [42]. This may be of particular importance, because dexamethasone—by decreasing mortality and the risk of severe neurological sequelae in adults with bacterial meningitis [49]—aggravated hippocampal injury and spatial learning deficits in animals [41, 50]. Studies that have investigated the long-term effects of melatonin or of a combination of melatonin and dexamethasone on neuropsychological function are necessary

Pharmacokinetic data qualify melatonin for adjunctive therapy in acute cerebral diseases: melatonin readily penetrates the blood-CSF barrier and cell membranes. The CSF:plasma concentration ratio has been reported to be ∼0.38 [51]. In our experiments, CSF levels of melatonin 24 h after the start of treatment were ∼20% of the corresponding serum concentrations. Melatonin concentrations of 0.1 μg/mL, which reduced cellular damage in organotypic hippocampal cultures, were achieved in the CSF of rabbits treated with the 20 mg/kg body weight dose (table 1)

Table 1
View larger version:
Table 1

Parameters of meningeal inflammation in cerebrospinal fluid (CSF) and concentrations of melatonin in CSF and serum of rabbits 12 and 24 h after the induction of bacterial meningitis

In conclusion, melatonin was protective in organotypic hippocampal cultures treated with S. pneumoniae and in human SH-SY5Y cells exposed to oxidative stress. In experimental pneumococcal meningitis, melatonin reduced neuronal injury by direct and indirect antioxidative mechanisms. Low toxicity and the ability to readily penetrate the blood-CSF barrier qualifies melatonin as a candidate for adjunctive therapy in bacterial meningitis

Previous SectionNext Section

Acknowledgment

We thank Uta Engelhardt for excellent technical support

Previous SectionNext Section

Footnotes

  • ↵Financial support: German Research Foundation, through the Center of Molecular Physiology of the Brain

  • Received August 25, 2004.
  • Accepted September 21, 2004.
Previous Section
 

References

  1. 1.↵
    1. Nau R,
    2. Brück W
    . Neuronal injury in bacterial meningitis: mechanisms and implications for therapy. Trends Neurosci 2002;25:38-45.
    CrossRefMedlineWeb of Science
  2. 2.↵
    1. Leib SL,
    2. Kim YS,
    3. Chow LL,
    4. Sheldon RA,
    5. Täuber MG
    . Reactive oxygen intermediates contribute to necrotic and apoptotic neuronal injury in an infant rat model of bacterial meningitis due to group B Streptococci. J Clin Invest 1996;98:2632-9.
    MedlineWeb of Science
  3. 3.↵
    1. Scheld WM,
    2. Koedel U,
    3. Nathan B,
    4. Pfister HW
    . Pathophysiology of bacterial meningitis: mechanism(s) of neuronal injury. J Infect Dis 2002;186 Suppl 2:S225-33.
    CrossRefMedline
  4. 4.↵
    1. Kim YS,
    2. Täuber MG
    . Neurotoxicity of glia activated by gram‐positive bacterial products depends on nitric oxide production. Infect Immun 1996;64:3148-53.
    Abstract/FREE Full Text
  5. 5.↵
    1. Duane PG,
    2. Rubins JB,
    3. Weisel HR,
    4. Janoff EN
    . Identification of hydrogen peroxide as a Streptococcus pneumoniae toxin for rat alveolar epithelial cells. Infect Immun 1993;61:4392-97.
    Abstract/FREE Full Text
  6. 6.↵
    1. Hirst RA,
    2. Sikand KS,
    3. Rutman A,
    4. Mitchell TJ,
    5. Andrew PW,
    6. O’Callaghan C
    . Relative roles of pneumolysin and hydrogen peroxide from Streptococcus pneumoniae in inhibition of ependymal ciliary beat frequency. Infect Immun 2000;68:1557-62.
    Abstract/FREE Full Text
  7. 7.↵
    1. Böttcher T,
    2. Gerber J,
    3. Wellmer A,
    4. et al
    . Rifampin reduces production of reactive oxygen species of CSF phagocytes and hippocampal neuronal apoptosis in experimental Streptococcus pneumoniae meningitis. J Infect Dis 2000;181:2095-8.
    CrossRefMedlineWeb of Science
  8. 8.↵
    1. Zawilska JB,
    2. Derbiszewska T,
    3. Sek B,
    4. Nowak JZ
    . Dopamine‐dependent cyclic AMP generating system in chick retina and its relation to melatonin biosynthesis. Neurochem Int 1995;27:535-43.
    CrossRefMedlineWeb of Science
  9. 9.↵
    1. Raikhlin NT,
    2. Kvetnoy IM,
    3. Tolkachev VN
    . Melatonin may be synthesised in enterochromaffin cells. Nature 1975;255:344-5.
    CrossRefMedline
  10. 10.↵
    1. Brzezinski A
    . Melatonin in humans. N Engl J Med 1997;336:186-95.
    CrossRefMedlineWeb of Science
  11. 11.↵
    1. Reppert SM,
    2. Weaver DR,
    3. Ebisawa T
    . Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 1994;13:1177-85.
    CrossRefMedlineWeb of Science
  12. 12.↵
    1. Reppert SM
    . Melatonin receptors: molecular biology of a new family of G protein–coupled receptors. J Biol Rhythms 1997;12:528-31.
    Abstract/FREE Full Text
  13. 13.↵
    1. Sugden D,
    2. Pickering H,
    3. Teh MT,
    4. Garratt PJ
    . Melatonin receptor pharmacology: toward subtype specificity. Biol Cell 1997;89:531-7.
    CrossRefMedlineWeb of Science
  14. 14.↵
    1. Witt‐Enderby PA,
    2. Bennett J,
    3. Jarzynka MJ,
    4. Firestine S,
    5. Melan MA
    . Melatonin receptors and their regulation: biochemical and structural mechanisms. Life Sci 2003;72:2183-98.
    CrossRefMedlineWeb of Science
  15. 15.↵
    1. Becker‐Andre M,
    2. Wiesenberg I,
    3. Schaeren‐Wiemers N,
    4. et al
    . Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor super family. J Biol Chem 1994;269:28531-4.
    Abstract/FREE Full Text
  16. 16.↵
    1. Guerrero JM,
    2. Pozo D,
    3. Garcia‐Maurino S,
    4. Osuna C,
    5. Molinero P,
    6. Calvo JR
    . Involvement of nuclear receptors in the enhanced IL‐2 production by melatonin in jurkat cells. Ann NY Acad Sci 2000;917:397-403.
    CrossRefMedlineWeb of Science
  17. 17.↵
    1. Tan DX,
    2. Reiter RJ,
    3. Manchester LC,
    4. et al
    . Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem 2002;2:181-97.
    CrossRefMedline
  18. 18.↵
    1. Kotler M,
    2. Rodriguez C,
    3. Sainz RM,
    4. Antolin I,
    5. Menendez‐Pelaez A
    . Melatonin increases gene expression for antioxidant enzymes in rat brain cortex. J Pineal Res 1998;24:83-9.
    MedlineWeb of Science
  19. 19.↵
    1. Okatani Y,
    2. Wakatsuki A,
    3. Kaneda C
    . Melatonin increases activities of glutathione peroxidase and superoxide dismutase in fetal rat brain. J Pineal Res 2000;28:89-96.
    CrossRefMedlineWeb of Science
  20. 20.↵
    1. Albarran MT,
    2. Lopez‐Burillo S,
    3. Pablos MI,
    4. Reiter RJ,
    5. Agapito MT
    . Endogenous rhythms of melatonin, total antioxidant status and superoxide dismutase activity in several tissues of chick and their inhibition by light. J Pineal Res 2001;30:227-33.
    CrossRefMedlineWeb of Science
  21. 21.↵
    1. Mayo JC,
    2. Sainz RM,
    3. Antoli I,
    4. Herrera F,
    5. Martin V,
    6. Rodriguez C
    . Melatonin regulation of antioxidant enzyme gene expression. Cell Mol Life Sci 2002;59:1706-13.
    CrossRefMedlineWeb of Science
  22. 22.↵
    1. Giusti P,
    2. Lipartiti M,
    3. Franceschini D,
    4. Schiavo N,
    5. Floreani M,
    6. Manev H
    . Neuroprotection by melatonin from kainate‐induced excitotoxicity in rats. FASEB J 1996;10:891-6.
    Abstract
  23. 23.↵
    1. Skaper SD,
    2. Ancona B,
    3. Facci L,
    4. Franceschini D,
    5. Giusti P
    . Melatonin prevents the delayed death of hippocampal neurons induced by enhanced excitatory neurotransmission and the nitridergic pathway. FASEB J 1998;12:725-31.
    Abstract/FREE Full Text
  24. 24.↵
    1. Sinha K,
    2. Degaonkar MN,
    3. Jagannathan NR,
    4. Gupta YK
    . Effect of melatonin on ischemia reperfusion injury induced by middle cerebral artery occlusion in rats. Eur J Pharmacol 2001;428:185-92.
    CrossRefMedlineWeb of Science
  25. 25.↵
    1. Pei Z,
    2. Pang SF,
    3. Cheung RT
    . Administration of melatonin after onset of ischemia reduces the volume of cerebral infarction in a rat middle cerebral artery occlusion stroke model. Stroke 2003;34:770-5.
    Abstract/FREE Full Text
  26. 26.↵
    1. Reiter RJ,
    2. Sainz RM,
    3. Lopez‐Burillo S,
    4. Mayo JC,
    5. Manchester LC,
    6. Tan DX
    . Melatonin ameliorates neurologic damage and neurophysiologic deficits in experimental models of stroke. Ann NY Acad Sci 2003;993:35-47.
    CrossRefMedlineWeb of Science
  27. 27.↵
    1. Kilic E,
    2. Ozdemir YG,
    3. Bolay H,
    4. Kelestimur H,
    5. Dalkara T
    . Pinealectomy aggravates and melatonin administration attenuates brain damage in focal ischemia. J Cereb Blood Flow Metab 1999;19:511-6.
    MedlineWeb of Science
  28. 28.↵
    1. Reiter RJ,
    2. Tan DX,
    3. Qi W,
    4. Manchester LC,
    5. Karbownik M,
    6. Calvo JR
    . Pharmacology and physiology of melatonin in the reduction of oxidative stress in vivo. Biol Signals Recept 2000;9:160-71.
    CrossRefMedlineWeb of Science
  29. 29.↵
    1. Huether G,
    2. Poeggeler B,
    3. Reimer A,
    4. George A
    . Effect of tryptophan administration on circulating melatonin levels in chicks and rats: evidence for stimulation of melatonin synthesis and release in the gastrointestinal tract. Life Sci 1992;51:945-53.
    CrossRefMedlineWeb of Science
  30. 30.↵
    1. George A,
    2. Poeggeler B,
    3. Huether G
    . Melatonin measurements in tissues: different recovery of endogenously contained and exogenously added melatonin. Adv Exp Med Biol 1996;398:691-6.
    MedlineWeb of Science
  31. 31.↵
    1. Coyle JT,
    2. Puttfarcken P
    . Oxidative stress, glutamate and neurodegenerative disorders. Science 1993;262:689-95.
    Abstract/FREE Full Text
  32. 32.↵
    1. Reiter RJ
    . Oxidative processes and antioxidative defense mechanisms in the aging brain. FASEB J 1995;9:526-33.
    Abstract
  33. 33.↵
    1. Finkel T,
    2. Holbrock NJ
    . Oxidants, oxidative stress and the biology of ageing. Nature 2000;408:239-47.
    CrossRefMedline
  34. 34.↵
    1. Love S
    . Oxidative stress in brain ischemia. Brain Pathol 1999;9:119-31.
    MedlineWeb of Science
  35. 35.↵
    1. Auer M,
    2. Pfister LA,
    3. Leppert D,
    4. Täuber MG,
    5. Leib SL
    . Effects of clinically used antioxidants in experimental pneumococcal meningitis. J Infect Dis 2000;182:347-50.
    Abstract/FREE Full Text
  36. 36.↵
    1. Loeffler JM,
    2. Ringer R,
    3. Hablützel M,
    4. Täuber MG,
    5. Leib SL
    . The free radical scavenger α‐phenyl‐tert‐butyl nitrone aggravates hippocampal apoptosis and learning deficits in experimental pneumococcal meningitis. J Infect Dis 2001;183:247-52.
    Abstract/FREE Full Text
  37. 37.↵
    1. Janzen EG,
    2. Poyer JL,
    3. Schaefer CF,
    4. Downs PE,
    5. DuBose CM
    . Biological spin trapping. II. Toxicity of nitrone spin traps: dose‐ranging in the rat. J Biochem Biophys Methods 1995;30:239-47.
    CrossRefMedlineWeb of Science
  38. 38.↵
    1. Jahnke G,
    2. Marr M,
    3. Myers C,
    4. Wilson R,
    5. Travlos G,
    6. Price C
    . Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague‐Dawley rats. Toxicol Sci 1999;50:271-9.
    Abstract/FREE Full Text
  39. 39.↵
    1. Mesenge C,
    2. Margaill C,
    3. Verrecchia C,
    4. Allix M,
    5. Boulu RG,
    6. Plotkine M
    . Protective effect of melatonin in a model of traumatic brain injury in mice. J Pineal Res 1998;25:41-6.
    MedlineWeb of Science
  40. 40.↵
    1. Sarrafzadeh AS,
    2. Thomale UW,
    3. Kroppenstedt SN,
    4. Unterberg AW
    . Neuroprotective effect of melatonin on cortical impact injury in the rat. Acta Neurochir (Wien) 2000;142:1293-9.
    CrossRefMedline
  41. 41.↵
    1. Zysk G,
    2. Brück W,
    3. Gerber J,
    4. Brück Y,
    5. Prange HW,
    6. Nau R
    . Anti‐inflammatory treatment influences neuronal apoptotic cell death in the dentate gyrus in experimental pneumococcal meningitis. J Neuropathol Exp Neurol 1996;55:722-8.
    MedlineWeb of Science
  42. 42.↵
    1. Nau R,
    2. Soto A,
    3. Brück W
    . Apoptosis of neurons in the dentate gyrus in humans suffering from bacterial meningitis. J Neuropathol Exp Neurol 1999;58:265-74.
    MedlineWeb of Science
  43. 43.↵
    1. Gerber J,
    2. Brück W,
    3. Stadelmann C,
    4. Bunkowski S,
    5. Lassmann H,
    6. Nau R
    . Expression of death‐related proteins in dentate granule cells in human bacterial meningitis. Brain Pathol 2001;11:422-31.
    MedlineWeb of Science
  44. 44.↵
    1. Schmidt H,
    2. Tlustochowska A,
    3. Stuertz K,
    4. et al
    . Organotypic hippocampal cultures: a model of brain tissue damage in Streptococcus pneumoniae meningitis. J Neuroimmunol 2001;113:30-9.
    CrossRefMedlineWeb of Science
  45. 45.↵
    1. Sacco S,
    2. Aquilini L,
    3. Ghezzi P,
    4. Pinza M,
    5. Guglielmotti A
    . Mechanism of the inhibitory effect of melatonin on tumor necrosis factor production in vivo and in vitro. Eur J Pharmacol 1998;343:249-55.
    CrossRefMedlineWeb of Science
  46. 46.↵
    1. Shafer LL,
    2. McNulty JA,
    3. Young MR
    . Assessment of melatonin’s ability to regulate cytokine production by macrophage and microglial cell types. J Neuroimmunol 2001;120:84-93.
    CrossRefMedlineWeb of Science
  47. 47.↵
    1. Tang YP,
    2. Ma YL,
    3. Chao CC,
    4. Chen KY,
    5. Lee EH
    . Enhanced glial cell line‐derived neurotrophic factor mRNA expression upon (−)‐deprenyl and melatonin treatments. J Neurosci Res 1998;53:593-604.
    CrossRefMedlineWeb of Science
  48. 48.↵
    1. Armstrong KJ,
    2. Niles LP
    . Induction of GDNF mRNA expression by melatonin in rat C6 glioma cells. Neuroreport 2002;13:473-5.
    CrossRefMedlineWeb of Science
  49. 49.↵
    1. de Gans J,
    2. van de Beek D,
    3. European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators
    . Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002;347:1549-56.
    CrossRefMedlineWeb of Science
  50. 50.↵
    1. Leib SL,
    2. Heimgartner C,
    3. Bifrare YD,
    4. Loeffler JM,
    5. Täuber MG
    . Dexamethasone aggravates hippocampal apoptosis and learning deficiency in pneumococcal meningitis in infant rats. Pediatr Res 2003;54:353-7.
    CrossRefMedlineWeb of Science
  51. 51.↵
    1. Vitte PA,
    2. Harthe C,
    3. Lestage P,
    4. Claustrat B,
    5. Bobillier P
    . Plasma, cerebrospinal fluid, and brain distribution of 14C‐melatonin in rat: a biochemical and autoradiographic study. J Pineal Res 1988;5:437-53.
    MedlineWeb of Science
| Table of Contents

This Article

  1. J Infect Dis. (2005) 191 (5): 783-790. doi: 10.1086/427816
  1. AbstractFree
  2. » Full Text (HTML)Free
  3. Full Text (PDF)Free

Classifications

Share

  1. Email this article

Navigate This Article

Current Issue

  1. March 1, 2012 205 (5)
  1. Journal of Infectious Diseases
  1. Alert me to new issues

Most